4.3 Article

Clinical and biological significance of HAX-1 overexpression in nasopharyngeal carcinoma

期刊

ONCOTARGET
卷 7, 期 11, 页码 12505-12524

出版社

IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.7274

关键词

exosomes; HAX-1; nasopharyngeal carcinoma; angiogenesis; prognosis

资金

  1. Chinese National Natural Science Foundation [81172841, 81202368, 81471603]
  2. China Postdoctoral Science Foundation [2013M541708]
  3. Natural Science Foundation of Jiangsu Province [SBK2015022581]
  4. project of 333 Natural Science Foundation of Jiangsu [BRA2013286]
  5. scientific and innovative research project of Nantong [BK2014003, HS2014007201HHS]
  6. Top Six Types of Talents Financial Assistance of Jiangsu Province [6]
  7. Jiangsu Provincial Health Department [Z201005]

向作者/读者索取更多资源

HS1-associated protein X-1 (HAX-1) is an important marker in many types of cancers and contributes to cancer progression and metastasis. We examined the expression of HAX-1 in nasopharyngeal carcinoma (NPC) and experimentally manipulated its expression. We observed that HAX-1 expression is elevated in NPC and is correlated with lymph node metastasis, M classification, clinical stage, and poor prognosis. In addition, overexpression of HAX-1 promoted NPC proliferation both in vitro and in vivo. Exosomes are potential carriers of pro-tumorigenic factors that participate in oncogenesis. We found that NPC-derived exosomes are enriched in HAX-1 and accelerate NPC tumor growth and angiogenesis in vitro and in vivo. Furthermore, we demonstrated that oncogenic HAX-1 facilitates the growth of NPC when it is transferred via exosomes to recipient human umbilical vein endothelial cells (HUVECs). Oncogenic HAX-1 also increases the proliferation, migration, and angiogenic activity of HUVECs. Our findings provide unique insight into the pathogenesis of NPC and underscore the need to explore novel therapeutic targets such as HAX-1 to improve NPC treatment.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据